Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland.
Mesoblast stock last closed at $1.39, up 1.46% from the previous day, and has decreased 56.7% in one year. It has underperformed other stocks in the Biotechnology industry by 0.29 percentage points. Mesoblast stock is currently +24.11% from its 52-week low of $1.12, and -72.85% from its 52-week high of $5.12.
As of Nov 28, 2023, there are 814.2M MESO shares outstanding. The market cap of MESO is $226.35M. In the last 24 hours, 54,042 MESO shares were traded.
You will need a brokerage account to access the NASDAQ market and buy MESO shares.
Based on our analysis, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro today.Open eToro Account
Now that you've selected the right brokerage, you'll need to fill out some personal details so you are able to buy MESO today.
Now that you have filled out your info on the best stock investing app, you need to deposit funds:
Watch the tutorial below for more details transferring funds into your new brokerage account.
After you have selected the best place to buy Mesoblast stock, it's important to evaluate their stock before you buy, so you actually comprehend the risk as well as the upside.
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on MESO's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge MESO's intrinsic value.
Using relative valuations ratios:
You can access additional valuation analysis on MESO's stock here.
Out of 3 Equities analysts who track MESO, the consensus analyst rating on MESO is a Hold
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Mesoblast stock forecast page.
Last year, MESO revenue was $7.50M. During the last 5 year, MESO's revenue has grown by -15.43% per year. This was slower than the Biotechnology industry average of 35.68%.
Find out more about MESO's earnings and revenue performance here.
In the past 12 months, executives and large shareholders at MESO have not bought or sold any shares.
Research more about who owns MESO stock here.
No, Mesoblast doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
There are two primary types of orders:
Hit the Open button and your broker will place your order.
If you require more assistance investing in stocks on eToro, click the helpful video below:
Now that you own some MESO shares, you'll want to keep up with your investment.
Make a watchlist to track your MESO stock.
To reiterate, here are the 6 steps to buy Mesoblast stock:
If you need a brokerage account, eToro is our favorite option.Get Started with eToro Today
If you would like to watch your new investment in Mesoblast, create a watchlist today.
How much does it cost to buy one Mesoblast share?
Is now a good time to buy Mesoblast stock?
What is the best way to buy Mesoblast stock?